Without robust data stewardship, including effective data sharing and global integration, the potential of cancer genomics will remain fragmented across projects, platforms, and jurisdictions, and this disaggregation limits reproducibility, equity, patient benefit, and societal value.
Abstract
Summary Cancer genomic data sharing is a core pillar of precision oncology, underpinning reproducibility, scalability, and equity. The ability to discover, access, integrate, interpret, and reuse cancer ‘omics data is a key determinant of precision oncology's value and benefit at scale. This work has been conducted as part of The Lancet Oncology Commission on Cancer Genomics and Precision Oncology to examine the practical data architecture required to support cancer genomics in research, clinical care, and health-system learning. We conclude that without robust data stewardship, including effective data sharing and global integration, the potential of cancer genomics will remain fragmented across projects, platforms, and jurisdictions. This disaggregation limits reproducibility, equity, patient benefit, and societal value. Healthcare systems must prioritise implementing fully efficient data ecosystems as a central challenge for precision oncology.
The Commission developed a value-based resource-stratified implementation framework, a system-readiness assessment tool, a precision oncology workforce competency-based framework, a precision oncology monitoring and evaluation framework, and principles for responsible data sharing and health-system learning.
R. Casolino, J. Mateo, E. D. de Vries et al.· The Lancet Oncology· 11 citations
Molecular pathology has become central to precision oncology, but German cancer registry data structures were designed for simpler molecular findings. This study argues that registries need a minimal, structured, and interoperable representation of molecular variants that remains compatible with data minimization and e...
J. Zohner, C. Kuhl, K. Schmid et al.· ESMO real world data and dig...· 0 citations
Precision oncology is redefining cancer therapeutics worldwide. In Australia, the integration of genomic medicine into routine clinical oncology remains inconsistently constrained by fragmented funding mechanisms, regional disparities, and a limited workforce. Understanding these structural and policy challenges is cru...
Samrin Liaqat, M. Khattak· Journal of Immunotherapy and...· 0 citations
Limited oncology workforce capacity, fragmented electronic health records (EHRs), and labor-intensive chart abstraction contribute substantially to under-enrollment in cancer clinical trials worldwide, particularly in resource-constrained settings. We evaluated a GPT-4o–based artificial intelligence platform design...
Yan Leyfman, A. Loaiza-Bonilla, E. Tuysuz et al.· JCO Global Oncology· 0 citations
Biobanks constitute foundational infrastructure for precision breast oncology, bridging discovery science and clinical implementation, and their capacity to integrate multi-omics datasets with functional tumor models positions them as essential drivers of individualized therapy.